- Home
- KNSA vs WRBY Comparison
KNSA vs WRBY Comparison
Compare KNSA & WRBY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KNSA
- WRBY
- Stock Information
- Founded
- KNSA 2015
- WRBY 2010
- Country
- KNSA United Kingdom
- WRBY United States
- Employees
- KNSA N/A
- WRBY N/A
- Industry
- KNSA Biotechnology: Pharmaceutical Preparations
- WRBY Ophthalmic Goods
- Sector
- KNSA Health Care
- WRBY Health Care
- Exchange
- KNSA Nasdaq
- WRBY Nasdaq
- Market Cap
- KNSA 1.9B
- WRBY 2.1B
- IPO Year
- KNSA 2018
- WRBY 2021
- Fundamental
- Price
- KNSA $28.44
- WRBY $21.73
- Analyst Decision
- KNSA Strong Buy
- WRBY Buy
- Analyst Count
- KNSA 5
- WRBY 15
- Target Price
- KNSA $38.80
- WRBY $23.33
- AVG Volume (30 Days)
- KNSA 707.0K
- WRBY 2.2M
- Earning Date
- KNSA 07-22-2025
- WRBY 08-07-2025
- Dividend Yield
- KNSA N/A
- WRBY N/A
- EPS Growth
- KNSA N/A
- WRBY N/A
- EPS
- KNSA N/A
- WRBY N/A
- Revenue
- KNSA $481,166,000.00
- WRBY $795,094,000.00
- Revenue This Year
- KNSA $37.21
- WRBY $16.13
- Revenue Next Year
- KNSA $5.32
- WRBY $13.87
- P/E Ratio
- KNSA N/A
- WRBY N/A
- Revenue Growth
- KNSA 59.45
- WRBY 13.94
- 52 Week Low
- KNSA $17.38
- WRBY $12.46
- 52 Week High
- KNSA $30.69
- WRBY $28.68
- Technical
- Relative Strength Index (RSI)
- KNSA 55.24
- WRBY 58.96
- Support Level
- KNSA $27.62
- WRBY $21.23
- Resistance Level
- KNSA $28.69
- WRBY $22.43
- Average True Range (ATR)
- KNSA 1.13
- WRBY 0.81
- MACD
- KNSA -0.28
- WRBY -0.14
- Stochastic Oscillator
- KNSA 45.78
- WRBY 48.15
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
About WRBY Warby Parker Inc.
Warby Parker Inc is a mission-driven, lifestyle brand that operates at the intersection of design, technology, healthcare, and social enterprise. The company predominantly derives revenue from the sales of eyewear products, optical services, and accessories. The firm sells products and services through its stores, website, and mobile apps. Revenue generated from eyewear products includes the sales of prescription and non-prescription optical glasses and sunglasses, contact lenses, eyewear accessories, and expedited shipping charges.